Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients

PeerJ

article

Lei Jin¹  Nan Zhang²  Qian Zhang²  Guoqian Ding¹  Zhenghan Yang²  Zhongtao Zhang¹ 

[1] Department of General Surgery, Beijing Friendship Hospital, Capital Medical University;National Clinical Research Center for Digestive Diseases;Department of Radiology, Beijing Friendship Hospital, Capital Medical University;Clinical Epidemiology and EBM Center, Beijing Friendship Hospital, Capital Medical University

关键词: Biomarkers;    Serum;    microRNAs;    Small RNA-sequencing;    Chemotherapy response;    Drug resistance;    Cisplatin;    Gastric cancer;    Bioinformatic analyse;    Area under the curves;   

DOI  :  10.7717/peerj.8943

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

BackgroundmicroRNAs (miRNAs) have been studied for their role in the early detection of several diseases. However, there is no current information on the systematic screening of serum-derived cisplatin resistance biomarkers in gastric cancer (GC).MethodsCisplatin-resistant GC cell lines were screened for dysregulated miRNAs using small RNA sequencing (sRNA-seq) and miRNAs were functionally annotated using bioinformatics analyses. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to validate the miRNA-relative transcription levels in GC cells and in 74 GC patients. We analyzed the associations between the clinical characteristics of the patients and their miRNA expression. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic value for serum-derived cisplatin resistance.ResultsSeven miRNAs were identified from 35 differentially expressed miRNAs between the MGC803/DDP and MGC803 cells in a public database. We found four miRNA candidates (miR-9-3p, miR-9-5p, miR-146a-5p, and miR-433-3p) that were significantly associated with chemotherapy responses in GC cells and patients. miR-9-5p (AUC = 0.856, 95% CI [0.773–0.939], p < 0.0001) and a combined group (miR-9-5p + miR-9-3p + miR-433-3p) (AUC = 0.915, 95% CI [0.856–0.975], P < 0.0001) distinguished chemoresistant GC patients from chemosensitive GC patients.ConclusionsOur study reveals the potential therapeutic use of two serum-based biomarkers, miR-9-5p and a combined group (miR-9-5p + miR-9-3p + miR-433-3p), as indicators for the successful use of cisplatin in GC patients.

【 授权许可】

CC BY